Skip to Content
Merck
All Photos(1)

Documents

EHU016691

Sigma-Aldrich

MISSION® esiRNA

targeting human RASA2

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CTGTATGCCAGCAGCTTGTTGTACACATCAAGGCATGCCATGGGTTGCCTCTCATAAATGGCCAAAGCTGTGACCCTTATGCAACAGTTTCTCTAGTGGGCCCTTCTAGGAATGACCAAAAGAAGACAAAAGTAAAGAAGAAAACAAGCAATCCGCAGTTTAATGAAATCTTTTATTTTGAGGTAACCAGATCCAGTAGTTACACCAGAAAGTCCCAGTTCCAGGTAGAAGAGGAGGACATTGAAAAGCTAGAAATCAGGATCGACTTGTGGAACAATGGAAACCTAGTCCAAGATGTTTTCCTAGGTGAGATTAAGGTTCCTGTGAACGTATTAAGAACTGATTCCTCTCATCAAGCCTGGTACTTGCTACAGCCAAGAGACAATGGAAACAAGTCATCCAAAACTGATGACCTGGGGTCTCTTC

Ensembl | human accession no.

ENSG00000155903

NCBI accession no.

NM_006506

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... RASA2(5922) , RASA2(5922)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Peng-Chieh Chen et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(31), 11473-11478 (2014-07-23)
Noonan syndrome (NS) is a relatively common genetic disorder, characterized by typical facies, short stature, developmental delay, and cardiac abnormalities. Known causative genes account for 70-80% of clinically diagnosed NS patients, but the genetic basis for the remaining 20-30% of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service